Injectables and TAF Most Exciting New HIV Treatments (Video)
June 2, 2016
On behalf of IFARA, Jeff Berry of Test Positive Aware Network (TPAN) and Positively Aware spoke with Dan Kuritzkes, M.D., and Joel E. Gallant, M.D., M.P.H., about advances in HIV treatment that were presented at the recent Conference on Retroviruses and Opportunistic Infections. The most important such developments are long-acting injectable formulations of antiretrovirals and a new version of tenofovir (tenofovir alafenamide [TAF]) that has fewer side effects than the current medication (tenofovir disoproxil fumarate [TDF, Viread]), both doctors agreed. Other drugs in development include a once-daily non-nucleoside transcriptase inhibitor and a nucleoside transcriptase inhibitor that may need to be taken only once a week. Dr. Gallant also noted research on a combination of two existing drugs that may lower the likelihood of developing drug resistance, which was not presented at this conference.
Watch the video to learn more:
The video above has been posted on TheBodyPRO.com with permission from our partners at the International Foundation for Alternative Research in AIDS (IFARA). Visit IFARA's website or YouTube channel to watch more video interviews from the CROI 2016 conference, as well as earlier meetings.
Barbara Jungwirth is a freelance writer and translator based in New York.
Follow Barbara on Twitter: @reliabletran.
Copyright © 2016 Remedy Health Media, LLC. All rights reserved.
This article was provided by TheBodyPRO. It is a part of the publication The 23rd Conference on Retroviruses and Opportunistic Infections.
Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)
The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.